Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
The breakthrough study from the University of Sheffield’s Neuroscience Institute and Healthy Lifespan Institute offers critical new insights into the so-called junk DNA, or DNA that was previously believed to be unimportant to the coding of the genome, and how it affects neurological disorders like Motor Neuron Disease (MND) and Alzheimer’s.
With a $2.5 million fund received from the Medical Research Future Fund (MRFF), a new genomics project led by WEHI will develop precision medicine and customized cancer therapy for Australians.
Rutgers researchers are seeking to develop the technology to modify or "edit" protein molecules in the body-;an advance that could spur major breakthroughs in human health.
Researchers from the Monash Biomedicine Discovery Institute have demonstrated how the common fungus Candida albicans evades immune responses using newly discovered imaging technologies. The researchers claim that this involves a fungus that can shape-shift in an “alien-like” manner to escape immune cells.
Recent work shows a novel mathematical approach to start comprehending how a cell’s nucleus is structured.
A developing area studies how clusters of molecules gather inside of cells, similar to how oil droplets form and separate from the water in a vinaigrette.
The human immune system is notably adept at evading tumor cells, which construct physical barriers, adopt masks, and restrain the immune system with molecular ploys.
By helping with digestion, supplying nutrients and metabolites, and collaborating with the immune system to ward off pathogens, gut bacteria have a significant impact on health.
According to a recent study conducted by scientists at Emory University in Atlanta, the administration of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive type of skin cancer, expedited their metastatic bone growth.
The Tob gene is well known for its connection to cancer. Scientists have discovered that this gene also has a significant role in lowering depression, fear, and anxiety in a multidisciplinary study that blends molecular biology with neuroscience.
According to a recent study, cancers can avoid both the immune system and cancer treatments that depend on it, including CAR T cells that have been genetically altered.
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
Cancer treatment is a lengthy procedure because surviving cancer cells frequently transform into aggressive versions that are no longer curable.
The treatment of various tumors has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. To target and combat specific forms of leukemia and lymphoma, the treatment employs genetically engineered T cells.
Tens of millions of individuals throughout the world suffer from antibiotic resistance every year. The CDC reports that more than 35,000 people die each year as a result of more than 2.8 million antibiotic-resistant infections that take place there each year.
Living cell factories can manufacture custom drug compounds and biofuels using biological enzymes.
A groundbreaking study from the Icahn School of Medicine at Mount Sinai found that astronauts are more likely to experience mutations that could be connected to spaceflight and increase their lifetime risk of acquiring cancer and heart disease.
The supply of a plant-derived anti-cancer drug can finally meet global demand after a team of scientists from Denmark and the U.S. engineered yeast to produce the precursor molecules, which could previously only be obtained in trace concentrations in the native plant.
The task of battling cancer cells can fatigue T cells employed in immunotherapy treatments, or they could shut down once they penetrate tumors. Researchers at the Gladstone Institutes and UC San Francisco have strengthened the therapeutic cells’ resistance via a CRISPR-based edit on their genomes.
Recent research from the School of Medicine has illuminated the development of the liver, lungs, and digestive system. This result may have significant ramifications for the comprehension of cancer.